Related Experiment Video
Updated: Aug 10, 2026
Simple and Rapid Method to Obtain High-quality Tumor DNA from Clinical-pathological Specimens Using Touch Imprint Cytology
Published on: March 21, 2018
Search for in vivo somatic mutations in the mitotic checkpoint gene, hMAD1, in human lung cancers
S Nomoto1, N Haruki, T Takahashi
1Laboratory of Ultrastructure Research, Aichi Cancer Center Research Institute, Nagoya, Japan.
Abstract:
We previously reported the presence of mitotic check-point impairment in about 40% of lung cancer cell lines. To gain an insight into the molecular basis of this impairment, we examined 49 lung cancer specimens for alterations in the hMAD1 mitotic checkpoint gene and identified a somatic, non-conservative missense mutation, which substitutes alanine (GCG) for threonine (ACG) at codon 299, together with a number of amino acid substituting, single nucleotide polymorphisms. This is the first demonstration of hMAD1 mutation in any type of human cancers. The present finding marks hMAD1 as a potential target, although with low frequency, for genetic alterations in lung cancer. Thus, further studies of hMAD1 dysfunction caused by other mechanisms appear to be warranted, as well as potential involvement of other components of the mitotic checkpoint.
Insights
Researchers identified a novel mutation in the hMAD1 gene in lung cancer specimens, marking it as a potential target for genetic alterations. Further studies are needed to explore other mechanisms of hMAD1 dysfunction.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Mitotic checkpoint impairment affects approximately 40% of lung cancer cell lines.
- Understanding the molecular basis of this impairment is crucial for targeted therapies.
Purpose of the Study:
- To investigate the molecular mechanisms underlying mitotic checkpoint impairment in lung cancer.
- To identify specific genetic alterations in the hMAD1 gene associated with lung cancer.
Main Methods:
- Analysis of 49 lung cancer specimens.
- Examination of the hMAD1 mitotic checkpoint gene for alterations.
- Identification of somatic mutations and single nucleotide polymorphisms.
Main Results:
- A somatic, non-conservative missense mutation in hMAD1 was identified, substituting threonine with alanine at codon 299.
- Several amino acid-substituting single nucleotide polymorphisms were also detected.
- This is the first reported mutation of hMAD1 in human cancers.
Conclusions:
- The hMAD1 gene is a potential, albeit infrequently targeted, site for genetic alterations in lung cancer.
- Further research into other mechanisms of hMAD1 dysfunction and the involvement of other mitotic checkpoint components is warranted.
